Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders.
Identifieur interne : 004592 ( PubMed/Checkpoint ); précédent : 004591; suivant : 004593Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders.
Auteurs : F. Federico [Italie] ; I L Simone ; V. Lucivero ; G. Iliceto ; M. De Mari ; P. Giannini ; D M Mezzapesa ; A. Tarantino ; P. LambertiSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1997.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (therapeutic use), Aspartic Acid (metabolism), Atrophy (pathology), Cerebral Cortex (pathology), Choline (metabolism), Corpus Striatum (metabolism), Creatinine (metabolism), Female, Globus Pallidus (metabolism), Globus Pallidus (pathology), Humans, Levodopa (therapeutic use), Magnetic Resonance Spectroscopy, Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (pathology), Parkinson Disease, Secondary (pathology), Phosphocreatine (metabolism), Protons (diagnostic use), Putamen (metabolism), Putamen (pathology), Supranuclear Palsy, Progressive (pathology).
- MESH :
- chemical , diagnostic use : Protons.
- chemical , metabolism : Aspartic Acid, Choline, Creatinine, Phosphocreatine.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug therapy : Parkinson Disease.
- metabolism : Corpus Striatum, Globus Pallidus, Putamen.
- pathology : Atrophy, Cerebral Cortex, Globus Pallidus, Parkinson Disease, Parkinson Disease, Secondary, Putamen, Supranuclear Palsy, Progressive.
- Aged, Female, Humans, Magnetic Resonance Spectroscopy, Middle Aged.
Abstract
Proton magnetic resonance spectroscopy (1H-MRS), localized to the lentiform nucleus, was carried out in 12 patients with idiopathic Parkinson's disease (IPD), seven patients with multiple-system atrophy (MSA), seven patients with progressive supranuclear palsy (PSP), and 10 healthy age-matched controls. The study assessed the level of N-acetylaspartate (NAA), creatine-phosphocreatine (Cr), and choline (Cho) in the putamen and globus pallidus of these patients. NAA/Cho and NAA/Cr ratios were significantly reduced in MSA and PSP patients. No significant difference was found between IPD patients and controls. These results suggest an NAA deficit, due to neuronal loss, in the lentiform nucleus of MSA and PSP patients. 1H-MRS is a noninvasive technique that can provide useful information regarding striatal neuronal loss in basal ganglia of patients with atypical parkinsonian disorders and represents a potential tool for diagnosing these disorders.
DOI: 10.1002/mds.870120611
PubMed: 9399213
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:9399213Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders.</title><author><name sortKey="Federico, F" sort="Federico, F" uniqKey="Federico F" first="F" last="Federico">F. Federico</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Clinical Neurology and Neuroradiology, University of Bari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Clinical Neurology and Neuroradiology, University of Bari</wicri:regionArea><wicri:noRegion>University of Bari</wicri:noRegion></affiliation></author><author><name sortKey="Simone, I L" sort="Simone, I L" uniqKey="Simone I" first="I L" last="Simone">I L Simone</name></author><author><name sortKey="Lucivero, V" sort="Lucivero, V" uniqKey="Lucivero V" first="V" last="Lucivero">V. Lucivero</name></author><author><name sortKey="Iliceto, G" sort="Iliceto, G" uniqKey="Iliceto G" first="G" last="Iliceto">G. Iliceto</name></author><author><name sortKey="De Mari, M" sort="De Mari, M" uniqKey="De Mari M" first="M" last="De Mari">M. De Mari</name></author><author><name sortKey="Giannini, P" sort="Giannini, P" uniqKey="Giannini P" first="P" last="Giannini">P. Giannini</name></author><author><name sortKey="Mezzapesa, D M" sort="Mezzapesa, D M" uniqKey="Mezzapesa D" first="D M" last="Mezzapesa">D M Mezzapesa</name></author><author><name sortKey="Tarantino, A" sort="Tarantino, A" uniqKey="Tarantino A" first="A" last="Tarantino">A. Tarantino</name></author><author><name sortKey="Lamberti, P" sort="Lamberti, P" uniqKey="Lamberti P" first="P" last="Lamberti">P. Lamberti</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1997">1997</date><idno type="RBID">pubmed:9399213</idno><idno type="pmid">9399213</idno><idno type="doi">10.1002/mds.870120611</idno><idno type="wicri:Area/PubMed/Corpus">004568</idno><idno type="wicri:Area/PubMed/Curation">004568</idno><idno type="wicri:Area/PubMed/Checkpoint">004592</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders.</title><author><name sortKey="Federico, F" sort="Federico, F" uniqKey="Federico F" first="F" last="Federico">F. Federico</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Clinical Neurology and Neuroradiology, University of Bari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Clinical Neurology and Neuroradiology, University of Bari</wicri:regionArea><wicri:noRegion>University of Bari</wicri:noRegion></affiliation></author><author><name sortKey="Simone, I L" sort="Simone, I L" uniqKey="Simone I" first="I L" last="Simone">I L Simone</name></author><author><name sortKey="Lucivero, V" sort="Lucivero, V" uniqKey="Lucivero V" first="V" last="Lucivero">V. Lucivero</name></author><author><name sortKey="Iliceto, G" sort="Iliceto, G" uniqKey="Iliceto G" first="G" last="Iliceto">G. Iliceto</name></author><author><name sortKey="De Mari, M" sort="De Mari, M" uniqKey="De Mari M" first="M" last="De Mari">M. De Mari</name></author><author><name sortKey="Giannini, P" sort="Giannini, P" uniqKey="Giannini P" first="P" last="Giannini">P. Giannini</name></author><author><name sortKey="Mezzapesa, D M" sort="Mezzapesa, D M" uniqKey="Mezzapesa D" first="D M" last="Mezzapesa">D M Mezzapesa</name></author><author><name sortKey="Tarantino, A" sort="Tarantino, A" uniqKey="Tarantino A" first="A" last="Tarantino">A. Tarantino</name></author><author><name sortKey="Lamberti, P" sort="Lamberti, P" uniqKey="Lamberti P" first="P" last="Lamberti">P. Lamberti</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1997" type="published">1997</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (therapeutic use)</term><term>Aspartic Acid (metabolism)</term><term>Atrophy (pathology)</term><term>Cerebral Cortex (pathology)</term><term>Choline (metabolism)</term><term>Corpus Striatum (metabolism)</term><term>Creatinine (metabolism)</term><term>Female</term><term>Globus Pallidus (metabolism)</term><term>Globus Pallidus (pathology)</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Magnetic Resonance Spectroscopy</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (pathology)</term><term>Parkinson Disease, Secondary (pathology)</term><term>Phosphocreatine (metabolism)</term><term>Protons (diagnostic use)</term><term>Putamen (metabolism)</term><term>Putamen (pathology)</term><term>Supranuclear Palsy, Progressive (pathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Protons</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Aspartic Acid</term><term>Choline</term><term>Creatinine</term><term>Phosphocreatine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term><term>Globus Pallidus</term><term>Putamen</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Atrophy</term><term>Cerebral Cortex</term><term>Globus Pallidus</term><term>Parkinson Disease</term><term>Parkinson Disease, Secondary</term><term>Putamen</term><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Magnetic Resonance Spectroscopy</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Proton magnetic resonance spectroscopy (1H-MRS), localized to the lentiform nucleus, was carried out in 12 patients with idiopathic Parkinson's disease (IPD), seven patients with multiple-system atrophy (MSA), seven patients with progressive supranuclear palsy (PSP), and 10 healthy age-matched controls. The study assessed the level of N-acetylaspartate (NAA), creatine-phosphocreatine (Cr), and choline (Cho) in the putamen and globus pallidus of these patients. NAA/Cho and NAA/Cr ratios were significantly reduced in MSA and PSP patients. No significant difference was found between IPD patients and controls. These results suggest an NAA deficit, due to neuronal loss, in the lentiform nucleus of MSA and PSP patients. 1H-MRS is a noninvasive technique that can provide useful information regarding striatal neuronal loss in basal ganglia of patients with atypical parkinsonian disorders and represents a potential tool for diagnosing these disorders.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9399213</PMID><DateCreated><Year>1998</Year><Month>02</Month><Day>10</Day></DateCreated><DateCompleted><Year>1998</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>6</Issue><PubDate><Year>1997</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders.</ArticleTitle><Pagination><MedlinePgn>903-9</MedlinePgn></Pagination><Abstract><AbstractText>Proton magnetic resonance spectroscopy (1H-MRS), localized to the lentiform nucleus, was carried out in 12 patients with idiopathic Parkinson's disease (IPD), seven patients with multiple-system atrophy (MSA), seven patients with progressive supranuclear palsy (PSP), and 10 healthy age-matched controls. The study assessed the level of N-acetylaspartate (NAA), creatine-phosphocreatine (Cr), and choline (Cho) in the putamen and globus pallidus of these patients. NAA/Cho and NAA/Cr ratios were significantly reduced in MSA and PSP patients. No significant difference was found between IPD patients and controls. These results suggest an NAA deficit, due to neuronal loss, in the lentiform nucleus of MSA and PSP patients. 1H-MRS is a noninvasive technique that can provide useful information regarding striatal neuronal loss in basal ganglia of patients with atypical parkinsonian disorders and represents a potential tool for diagnosing these disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Federico</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neurology and Neuroradiology, University of Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simone</LastName><ForeName>I L</ForeName><Initials>IL</Initials></Author><Author ValidYN="Y"><LastName>Lucivero</LastName><ForeName>V</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Iliceto</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>De Mari</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Giannini</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Mezzapesa</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Tarantino</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lamberti</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011522">Protons</NameOfSubstance></Chemical><Chemical><RegistryNumber>020IUV4N33</RegistryNumber><NameOfSubstance UI="D010725">Phosphocreatine</NameOfSubstance></Chemical><Chemical><RegistryNumber>30KYC7MIAI</RegistryNumber><NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>AYI8EX34EU</RegistryNumber><NameOfSubstance UI="D003404">Creatinine</NameOfSubstance></Chemical><Chemical><RegistryNumber>N91BDP6H0X</RegistryNumber><NameOfSubstance UI="D002794">Choline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001224">Aspartic Acid</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001284">Atrophy</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002540">Cerebral Cortex</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002794">Choline</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003342">Corpus Striatum</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003404">Creatinine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005917">Globus Pallidus</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D009682">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010302">Parkinson Disease, Secondary</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010725">Phosphocreatine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011522">Protons</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011699">Putamen</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013494">Supranuclear Palsy, Progressive</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>12</Month><Day>17</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>12</Month><Day>17</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9399213</ArticleId><ArticleId IdType="doi">10.1002/mds.870120611</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Italie</li></country></list><tree><noCountry><name sortKey="De Mari, M" sort="De Mari, M" uniqKey="De Mari M" first="M" last="De Mari">M. De Mari</name><name sortKey="Giannini, P" sort="Giannini, P" uniqKey="Giannini P" first="P" last="Giannini">P. Giannini</name><name sortKey="Iliceto, G" sort="Iliceto, G" uniqKey="Iliceto G" first="G" last="Iliceto">G. Iliceto</name><name sortKey="Lamberti, P" sort="Lamberti, P" uniqKey="Lamberti P" first="P" last="Lamberti">P. Lamberti</name><name sortKey="Lucivero, V" sort="Lucivero, V" uniqKey="Lucivero V" first="V" last="Lucivero">V. Lucivero</name><name sortKey="Mezzapesa, D M" sort="Mezzapesa, D M" uniqKey="Mezzapesa D" first="D M" last="Mezzapesa">D M Mezzapesa</name><name sortKey="Simone, I L" sort="Simone, I L" uniqKey="Simone I" first="I L" last="Simone">I L Simone</name><name sortKey="Tarantino, A" sort="Tarantino, A" uniqKey="Tarantino A" first="A" last="Tarantino">A. Tarantino</name></noCountry><country name="Italie"><noRegion><name sortKey="Federico, F" sort="Federico, F" uniqKey="Federico F" first="F" last="Federico">F. Federico</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004592 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 004592 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:9399213
|texte= Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:9399213" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |